Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
CTI Life Sciences Fund

CTI Life Sciences Fund

A venture capital firm in Canada that focuses on pharmaceutical development

CTI Life Sciences Fund is a venture capital firm in Canada that focuses on pharmaceutical development. Founded 2006 in Montréal, Quebec, Canada, it invests in series A, series B, series C, and venture rounds. Its portfolio companies include Visterra, PreciThera, PHEMI Health Systems, SutroVax, CellAegis Devices, ILKOS Therapeutic, IMV Inc, DalCor Pharmaceuticals, and Zymeworks. As of February 2020, CTI Life Sciences Fund has made 23 investments. Their most recent investment was on October 5, 2017, when Visterra raised $23.6M. CTI Life Sciences Fund has had seven exits, the most notable of which include Zymeworks, Visterra, and Medicago. The company has raised two funds, their latest being CTI Life Sciences Fund II. This fund was announced on January 15, 2015 and raised a total of $134M.

Timeline

2006
Founded

Invested in

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Isabelle Kirkwood
May 10, 2021
BetaKit
Montréal-based venture capital firm CTI Life Sciences Fund has raised $100 million CAD in the first close of its third venture fund. The fund's...

References

Golden logo
By using this site, you agree to our Terms & Conditions.